{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:41Z","timestamp":1793406881065,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012905","name":"Department of Science and Technology of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015508","name":"Shandong Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015508","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH091"],"award-info":[{"award-number":["ZR2023MH091"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020206","name":"Shandong Province Health Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.phrs.2025.107647","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T02:50:30Z","timestamp":1738983030000},"page":"107647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7330-1151","authenticated-orcid":false,"given":"Hongsheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9453","authenticated-orcid":false,"given":"Yanli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyong","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10290","key":"10.1016\/j.phrs.2025.107647_bib1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of nafld","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107647_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2025.107647_bib4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2025.107647_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107647_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, nafld, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr. Diab Rep."},{"issue":"6","key":"10.1016\/j.phrs.2025.107647_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1159\/000514953","article-title":"Nash\/liver fibrosis prevalence and incidence of nonliver comorbidities among people with nafld and incidence of nafld by metabolic comorbidities: lessons from south korea","volume":"39","author":"Park","year":"2021","journal-title":"Dig. Dis."},{"key":"10.1016\/j.phrs.2025.107647_bib8","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.phrs.2025.107647_bib9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map","volume":"53","author":"Kumar","year":"2021","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4239\/wjd.v12.i1.84","article-title":"Novel glucose-lowering drugs for non-alcoholic fatty liver disease","volume":"12","author":"Fu","year":"2021","journal-title":"World J. Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2025.107647_bib12","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for nafld: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2025.107647_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1871529X18666180206160838","article-title":"Sodium-glucose cotransporter 2 inhibitors: glucose lowering against other hypoglycemic agents","volume":"18","author":"Avranas","year":"2018","journal-title":"Cardiovasc Hematol. Disord. Drug Targets"},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/ijms19010137","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice","volume":"19","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2025.107647_bib15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting postprandial hyperglycemia in zucker diabetic fatty rats with an sglt2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle","volume":"66","author":"O'Brien","year":"2017","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.phrs.2025.107647_bib16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J. Diabetes Invest."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41574-022-00776-2","article-title":"Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice","volume":"19","author":"Lim","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107647_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial","volume":"9","author":"Han","year":"2020","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4314\/ahs.v22i3.42","article-title":"Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"22","author":"Tang","year":"2022","journal-title":"Afr. Health Sci."},{"issue":"10","key":"10.1016\/j.phrs.2025.107647_bib22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.phrs.2025.107647_bib23","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"Aasld practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2025.107647_bib24","doi-asserted-by":"crossref","unstructured":"Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the italian association for the study of the liver (aisf), the italian society of diabetology (sid) and the italian society of obesity (sio), Eat Weight Disord 27(5) (2022) 1603-1619.","DOI":"10.1007\/s40519-021-01287-1"},{"key":"10.1016\/j.phrs.2025.107647_bib25","doi-asserted-by":"crossref","unstructured":"Easl Clinical Practice Guidelines: Management of Alcohol-related Liver Disease, J Hepatol 69(1) (2018) 154-181.","DOI":"10.1016\/j.jhep.2018.03.018"},{"key":"10.1016\/j.phrs.2025.107647_bib26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.phrs.2025.107647_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the prisma 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2025.107647_bib28","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"issue":"7414","key":"10.1016\/j.phrs.2025.107647_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.phrs.2025.107647_bib30","doi-asserted-by":"crossref","unstructured":"J.W. Eriksson, P. Lundkvist, P. Jansson, L. Johansson, M. Kvarnstrom, L. Moris, T. Miliotis, G. Forsberg, U. Riserus, L. Lind, A. Et, Effects of Dapagliflozin and N-3 Carboxylic Acids on Non-alcoholic Fatty Liver Disease in People with Type 2 Diabetes: A Double-blind Randomised Placebo-controlled Study 61(9) (2018) 1923-1934.","DOI":"10.1007\/s00125-018-4675-2"},{"issue":"12","key":"10.1016\/j.phrs.2025.107647_bib31","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/ph15121516","article-title":"The impact of an sglt2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients","volume":"15","author":"Elhini","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.phrs.2025.107647_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.phrs.2025.107647_bib33","doi-asserted-by":"crossref","unstructured":"M. Hussain, M. Babar, S. Tariq, M.I. Ahmad, L. Akhtar, Therapeutic Outcome of Dapagliflozin on Various Parameters in Non-alcoholic Fatty Liver Disease (nafld) patients 42(2) (2022) 290-296.","DOI":"10.1007\/s13410-021-00980-2"},{"issue":"10","key":"10.1016\/j.phrs.2025.107647_bib34","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"issue":"11","key":"10.1016\/j.phrs.2025.107647_bib36","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.107647_bib37","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (e-lift trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2025.107647_bib38","doi-asserted-by":"crossref","unstructured":"H. Takahashi, T. Kessoku, M. Kawanaka, M. Nonaka, H. Hyogo, H. Fujii, T. Nakajima, K. Imajo, K. Tanaka, Y. Kubotsu, A. Et, Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with nafld 6(1) (2022) 120-132.","DOI":"10.1002\/hep4.1696"},{"issue":"7","key":"10.1016\/j.phrs.2025.107647_bib39","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1136\/jim-2020-001621","article-title":"Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"69","author":"Aso","year":"2021","journal-title":"J. Invest. Med"},{"key":"10.1016\/j.phrs.2025.107647_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/757929","article-title":"Biomarkers in nonalcoholic fatty liver disease","volume":"28","author":"Neuman","year":"2014","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107647_bib41","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","article-title":"Abnormal liver enzymes: a review for clinicians","volume":"13","author":"Kalas","year":"2021","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107647_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/145754","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease","volume":"2012","author":"Obika","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/j.phrs.2025.107647_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of sglt2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107647_bib44","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14656566.2024.2360078","article-title":"Nidhi, Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"25","author":"Parveen","year":"2024","journal-title":"Expert Opin. Pharm."},{"issue":"8","key":"10.1016\/j.phrs.2025.107647_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J. Diabetes Complicat."},{"issue":"9","key":"10.1016\/j.phrs.2025.107647_bib46","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s13300-022-01296-y","article-title":"Clinical benefit of switching from low-dose to high-dose empagliflozin in patients with type 2 diabetes","volume":"13","author":"Matsumura","year":"2022","journal-title":"Diabetes Ther."},{"issue":"7","key":"10.1016\/j.phrs.2025.107647_bib47","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-022-00814-z","article-title":"Nafld in normal weight individuals","volume":"14","author":"Distefano","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.clinthera.2021.01.021","article-title":"Therapy for nonalcoholic fatty liver disease: current options and future directions","volume":"43","author":"Campbell","year":"2021","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2025.107647_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3945\/an.116.013730","article-title":"Nutritional approaches to achieve weight loss in nonalcoholic fatty liver disease","volume":"8","author":"Hsu","year":"2017","journal-title":"Adv. Nutr."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (nafld): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"Bmc Endocr. Disord."},{"issue":"4","key":"10.1016\/j.phrs.2025.107647_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.101876","article-title":"Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Sun","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107647_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links nafld to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14218\/JCTH.2014.00037","article-title":"Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy","volume":"3","author":"Zhang","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib55","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"Apoc3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","journal-title":"J. Clin. Lipido"},{"issue":"6","key":"10.1016\/j.phrs.2025.107647_bib56","article-title":"The association of the steatosis severity, nafld fibrosis score and fib-4 index with atherogenic dyslipidaemia in adult patients with nafld: a cross-sectional study","volume":"75","author":"Tutunchi","year":"2021","journal-title":"Int. J. Clin. Pr."},{"issue":"9","key":"10.1016\/j.phrs.2025.107647_bib57","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased ldl (low-density lipoprotein) and decreased triglycerides with sglt2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107647_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"Sglt2-inhibition increases total, ldl, and hdl cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.phrs.2025.107647_bib59","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00535-024-02122-x","article-title":"Effects of luseogliflozin on suspected masld in patients with diabetes: a pooled meta-analysis of phase iii clinical trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107647_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145889","article-title":"Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model","volume":"132","author":"Guzman","year":"2022","journal-title":"J. Clin. Invest"},{"issue":"637","key":"10.1016\/j.phrs.2025.107647_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh3831","article-title":"Hepatic irf3 fuels dysglycemia in obesity through direct regulation of ppp2r1b","volume":"14","author":"Patel","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.phrs.2025.107647_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094416","article-title":"Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors","volume":"22","author":"Yanai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2025.107647_bib63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41591-022-02120-7","article-title":"Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the trimaster study","volume":"29","author":"Shields","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.phrs.2025.107647_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003149","article-title":"Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the imi direct cohorts","volume":"17","author":"Atabaki-Pasdar","year":"2020","journal-title":"PloS Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12020-023-03642-x","article-title":"Mechanisms and risk factors of metabolic syndrome in children and adolescents","volume":"84","author":"Codazzi","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.phrs.2025.107647_bib66","doi-asserted-by":"crossref","first-page":"2217287","DOI":"10.1080\/0886022X.2023.2217287","article-title":"Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis","volume":"45","author":"Liu","year":"2023","journal-title":"Ren. Fail"},{"key":"10.1016\/j.phrs.2025.107647_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106396","article-title":"Sglt2-inhibitors are effective and safe in the elderly: the sold study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.phrs.2025.107647_bib68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40272-024-00623-z","article-title":"Dapagliflozin and empagliflozin in paediatric indications: a systematic review","volume":"26","author":"Lava","year":"2024","journal-title":"Paediatr. Drugs"},{"issue":"5","key":"10.1016\/j.phrs.2025.107647_bib69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107647_bib70","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (e-lift trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.phrs.2025.107647_bib71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.phrs.2025.107647_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.phrs.2025.107647_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/nu14102178","article-title":"Reduction of de novo lipogenesis mediates beneficial effects of isoenergetic diets on fatty liver: mechanistic insights from the medea randomized clinical trial","volume":"14","author":"Costabile","year":"2022","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.phrs.2025.107647_bib74","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/dom.13224","article-title":"Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin","volume":"20","author":"Polidori","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2025.107647_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114445","article-title":"Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models","volume":"161","author":"Kim","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2025.107647_bib76","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"Mechanisms in endocrinology: sglt2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2025.107647_bib77","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.2147\/DDDT.S388823","article-title":"Canagliflozin attenuates hepatic steatosis and atherosclerosis progression in western diet-fed apoe-knockout mice","volume":"16","author":"Zuo","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2025.107647_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The sglt2 inhibitor empagliflozin negatively regulates il-17\/il-23 axis-mediated inflammatory responses in t2dm with nafld via the ampk\/mtor\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107647_bib79","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107647_bib80","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cld.2015.10.015","article-title":"Emerging therapies for nonalcoholic fatty liver disease","volume":"20","author":"Hameed","year":"2016","journal-title":"Clin. Liver Dis."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:42:25Z","timestamp":1762353745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":80,"alternative-id":["S1043661825000726"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107647","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107647"}}